Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascendis Pharma ( (ASND) ) has provided an update.
On March 23, 2026, Ascendis Pharma held its Annual General Meeting in Denmark, with 90.16% of outstanding ordinary shares represented, and shareholders approved the audited annual report for 2025 while discharging the board and management from liability. Investors also agreed to carry forward the 2025 consolidated loss of EUR 228 million into 2026, signaling continued support for the company’s long-term strategy despite ongoing losses.
Shareholders re-elected the entire board and added former industry executive Jean-Jacques Bienaimé as a new non-executive director, extending board terms to the 2027 annual meeting and reinforcing experienced governance at the biotech group. The meeting further reappointed Deloitte as auditor and granted the board a new share repurchase authorization valid until March 2031, expanding its capital management flexibility alongside existing buyback mandates that include an authorization expiring in May 2026.
The most recent analyst rating on (ASND) stock is a Buy with a $273.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong margins, and a move to positive operating/free cash flow) but is held back by balance-sheet risk (negative equity and high debt) and unprofitable earnings (negative P/E). Technicals are neutral-to-slightly cautious, while the latest earnings call adds support via upbeat guidance and commercial/pipeline momentum despite elevated operating expenses and near-term volatility risks.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company listed in the U.S. that develops and commercializes therapies, with its share capital represented both by ordinary shares and American Depositary Shares. The company operates within the global life sciences and healthcare sector and is subject to Danish corporate governance rules and U.S. securities regulation for foreign private issuers.
Average Trading Volume: 678,014
Technical Sentiment Signal: Buy
Current Market Cap: $13.38B
See more insights into ASND stock on TipRanks’ Stock Analysis page.